Clover Health Investments, Corp.
Clover Health Investments, Corp. (CLOV) Financial Performance & Income Statement Overview
Analyze Clover Health Investments, Corp. (CLOV) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Clover Health Investments, Corp. (CLOV) Income Statement & Financial Overview
Explore comprehensive income reports for Clover Health Investments, Corp. CLOV, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $462.33M | $336.96M | $330.99M | $356.26M |
| Cost of Revenue | $353.44M | $243.04M | $249.77M | $248.35M |
| Gross Profit | $108.89M | $93.92M | $81.21M | $107.91M |
| Gross Profit Ratio | $0.24 | $0.28 | $0.25 | $0.30 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $109.70M | $115.02M | $90.20M | $99.92M |
| Operating Expenses | $110.16M | $115.37M | $90.00M | $100.73M |
| Total Costs & Expenses | $463.61M | $358.41M | $339.77M | $349.07M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $466000.00 | $344000.00 | $339000.00 | $330000.00 |
| EBITDA | -$808000.00 | -$21.14M | -$8.45M | $7.50M |
| EBITDA Ratio | -$0.002 | -$0.06 | -$0.03 | $0.02 |
| Operating Income | -$1.27M | -$21.45M | -$8.79M | $7.19M |
| Operating Income Ratio | -$0.003 | -$0.06 | -$0.03 | $0.02 |
| Other Income/Expenses (Net) | $0.00 | -$33000.00 | $0.00 | -$17000.00 |
| Income Before Tax | -$1.27M | -$21.48M | -$8.79M | $7.17M |
| Income Before Tax Ratio | -$0.003 | -$0.06 | -$0.03 | $0.02 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$1.27M | -$22.09M | -$9.15M | $7.41M |
| Net Income Ratio | -$0.003 | -$0.07 | -$0.03 | $0.02 |
| EPS | -$0.003 | -$0.04 | -$0.02 | $0.01 |
| Diluted EPS | -$0.003 | -$0.04 | -$0.02 | $0.01 |
| Weighted Avg Shares Outstanding | $497.06M | $491.87M | $490.18M | $487.48M |
| Weighted Avg Shares Outstanding (Diluted) | $497.06M | $491.87M | $490.18M | $495.18M |
Financial performance has remained strong, with revenue growing from $356.26M in Q2 2024 to $462.33M in Q1 2025. Gross profit continued to perform well, with margins at 24% in the latest quarter. Operating income reached -$1.27M in Q1 2025, holding a steady -0% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$808000.00. Net income rose to -$1.27M, keeping EPS at -$0.003. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan